NEW YORK -- Unlike other atypical antipsychotics, ziprasidone was not found to increase the risk for diabetes or cardiovascular disease in an analysis of data from the Clinical Antipsychotic Trials in Intervention Effectiveness study.
Results from CATIE indicated that patients with schizophrenia at baseline are at increased risk of coronary heart disease (CHD), compared with age- and sex-matched controls, according to Brian J. Cuffel, Ph.D., of Pfizer Inc.
CATIE included 1,493 patients with schizophrenia recruited from 57 clinical facilities in the United States. At baseline, fasting laboratory values were obtained and patients randomly assigned to treatment with olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), or ziprasidone (Geodon).
Baseline risk for CHD was significantly elevated in men with schizophrenia, at 9.4%, compared with matched controls, whose baseline risk was 7%. The baseline risk for women with schizophrenia was 6.3%, compared with 4.2% for controls.
Factors that contributed to this increased risk included higher rates of smoking, diabetes, and hypertension, and low levels of high-density lipoproteins, according to one of the initial publications from CATIE (Schizoph. Res. 2005;80:45-53).
The availability of data from CATIE also provides an important opportunity to assess medication-attributable risk for CHD disease and secondary …